Cargando…

Gallic acid enhances anti-lymphoma function of anti-CD19 CAR-T cells in vitro and in vivo

Chimeric antigen receptor T (CAR-T) cell targeting CD19 antigen has achieved exhilarative clinical efficacy in B-cell malignancies. However, challenges still remain for the currently approved anti-CD19 CAR-T therapies, including high recurrence rates, side effects and resistance. Herein, we aim to e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luo, Zhiqiang, Shi, Jiaru, Jiang, Qiyao, Yu, Guohua, Li, Xiaorui, Yu, Zhuoying, Wang, Jianxun, Shi, Yuanyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985527/ https://www.ncbi.nlm.nih.gov/pubmed/36871129 http://dx.doi.org/10.1186/s43556-023-00122-6

Ejemplares similares

Co-Expression of miR155 or LSD1 shRNA Increases the Anti-Tumor Functions of CD19 CAR-T Cells
por: Zhang, Jing, et al.
Publicado: (2022)

Anti-inflammatory and antioxidative effects of gallic acid on experimental dry eye: in vitro and in vivo studies
por: Li, Kexin, et al.
Publicado: (2023)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
por: Feng, Jia, et al.
Publicado: (2022)

Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
por: Feng, Jia, et al.
Publicado: (2021)

Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma
por: Caimi, Paolo F., et al.
Publicado: (2021)

Evaluation of Gallic Acid-Coated Gold Nanoparticles as an Anti-Aging Ingredient
por: Wu, Yun-Zhen, et al.
Publicado: (2021)

Characterization of the Therapeutic Effects of Novel Chimeric Antigen Receptor T Cells Targeting CD38 on Multiple Myeloma
por: Li, Xiaorui, et al.
Publicado: (2021)

Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody
por: Ye, Jing, et al.
Publicado: (2022)

Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
por: Yin, Yuzhen, et al.
Publicado: (2022)

Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma
por: McDermott, Kathleen, et al.
Publicado: (2019)

Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma
por: Monfrini, Chiara, et al.
Publicado: (2022)

In-vitro osteoblast proliferation and in-vivo anti-osteoporotic activity of Bombax ceiba with quantification of Lupeol, gallic acid and β-sitosterol by HPTLC and HPLC
por: Chauhan, Shashi, et al.
Publicado: (2018)

In vitro and in vivo anti-lymphoma effects of Ophiorrhiza pumila extract
por: Fan, Lixia, et al.
Publicado: (2022)

Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma
por: Zhang, Peiling, et al.
Publicado: (2022)

Retracted: Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Ibrutinib improves the efficacy of anti‐CD19‐CAR T‐cell therapy in patients with refractory non‐Hodgkin lymphoma
por: Liu, Meijing, et al.
Publicado: (2021)

Anti-Inflammatory and Anti-Allergic Activities of Pentaherb Formula, Moutan Cortex (Danpi) and Gallic Acid
por: Liu, Kelly Y. P., et al.
Publicado: (2013)

Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy
por: Zhu, Haibo, et al.
Publicado: (2021)

Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting
por: Rotolo, Antonia, et al.
Publicado: (2018)

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
por: Wei, Jia, et al.
Publicado: (2019)

Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma
por: Jia, Qingzhu, et al.
Publicado: (2021)

Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma
por: Graham, Charlotte Elizabeth, et al.
Publicado: (2021)

Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma
por: Montraveta, Arnau, et al.
Publicado: (2014)

Safety and feasibility of anti-CD19 CAR T cells with fully-human binding domains in patients with B-cell lymphoma
por: Brudno, Jennifer N., et al.
Publicado: (2020)

Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
por: Sheikh, Semira, et al.
Publicado: (2021)

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
por: Scholler, Nathalie, et al.
Publicado: (2022)

HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma
por: Bourbon, Estelle, et al.
Publicado: (2022)

Quantitative Analysis and In vitro Anti-inflammatory Effects of Gallic Acid, Ellagic Acid, and Quercetin from Radix Sanguisorbae
por: Seo, Chang-Seob, et al.
Publicado: (2016)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo
por: Zhang, Qian, et al.
Publicado: (2022)

Tenacigenin B Has Anti-Tumor Effect in Lymphoma by In Vitro and In Vivo Study
por: Dai, Xingbin, et al.
Publicado: (2019)

Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
por: Atilla, Pinar Ataca, et al.
Publicado: (2022)

Antifibrotic effects of gallic acid on hepatic stellate cells: In vitro and in vivo mechanistic study
por: El-Lakkany, Naglaa M., et al.
Publicado: (2018)

Influence of gallic and tannic acid on therapeutic properties of acarbose in vitro and in vivo in Drosophila melanogaster
por: Oboh, Ganiyu, et al.
Publicado: (2019)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia In Vitro and In Vivo
por: Rennert, Paul D., et al.
Publicado: (2021)

Challenges of Anti-Mesothelin CAR-T-Cell Therapy
por: Zhai, Xuejia, et al.
Publicado: (2023)

Anti-microbial Effects In Vitro and In Vivo of Alstonia scholaris
por: Zhao, Yun-Li, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lhhvkv8t6bhloammcit158qhhu